<code id='CC52C6A7CA'></code><style id='CC52C6A7CA'></style>
    • <acronym id='CC52C6A7CA'></acronym>
      <center id='CC52C6A7CA'><center id='CC52C6A7CA'><tfoot id='CC52C6A7CA'></tfoot></center><abbr id='CC52C6A7CA'><dir id='CC52C6A7CA'><tfoot id='CC52C6A7CA'></tfoot><noframes id='CC52C6A7CA'>

    • <optgroup id='CC52C6A7CA'><strike id='CC52C6A7CA'><sup id='CC52C6A7CA'></sup></strike><code id='CC52C6A7CA'></code></optgroup>
        1. <b id='CC52C6A7CA'><label id='CC52C6A7CA'><select id='CC52C6A7CA'><dt id='CC52C6A7CA'><span id='CC52C6A7CA'></span></dt></select></label></b><u id='CC52C6A7CA'></u>
          <i id='CC52C6A7CA'><strike id='CC52C6A7CA'><tt id='CC52C6A7CA'><pre id='CC52C6A7CA'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:6239
          Illustration of a hospital with stacks of dollar bills on top – private equity coverage from STAT
          Adobe

          Private equity firms are rapidly buying their way into the U.S. health care system, and as they do, new research finds they tend to increase costs and may also harm quality.

          A new BMJ systematic review rounded up 55 studies on the effects of private equity buyouts in health care globally to flesh out an overarching conclusion. The team of researchers found that private equity ownership generally means higher costs for patients, insurance companies, and government programs. The effects on quality were mixed, with more evidence showing that such financial investors degrade quality.

          advertisement

          “This is really the first widespread snapshot of what the impacts of all these developments are,” said Alexander Borsa, a study author and doctoral candidate at Columbia University.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          First U.S. drug developed to treat liver disease MASH is approved
          First U.S. drug developed to treat liver disease MASH is approved

          AdobeTheFoodandDrugAdministrationonThursdayapprovedthefirstmedicinedevelopedspecificallytotreatthese

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Novo acquires Inversago for up to $1 billion

          LISELOTTESABROE/Scanpix/AFPviaGettyImagesFreshoffofthenewsthatitsdrugWegovymaynotjusthelppeoplelosew